1. Home
  2. EEA vs TENX Comparison

EEA vs TENX Comparison

Compare EEA & TENX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo The European Equity Fund Inc.

EEA

The European Equity Fund Inc.

N/A

Current Price

$10.32

Market Cap

73.5M

Sector

Finance

ML Signal

N/A

Logo Tenax Therapeutics Inc.

TENX

Tenax Therapeutics Inc.

N/A

Current Price

$1.92

Market Cap

74.1M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
EEA
TENX
Founded
1986
1967
Country
Germany
United States
Employees
N/A
16
Industry
Trusts Except Educational Religious and Charitable
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
73.5M
74.1M
IPO Year
N/A
2001

Fundamental Metrics

Financial Performance
Metric
EEA
TENX
Price
$10.32
$1.92
Analyst Decision
Buy
Analyst Count
0
10
Target Price
N/A
★ $12.56
AVG Volume (30 Days)
19.9K
★ 3.0M
Earning Date
01-01-0001
11-11-2026
Dividend Yield
★ 1.92%
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$9.62
$1.31
52 Week High
$11.43
$19.40

Technical Indicators

Market Signals
Indicator
EEA
TENX
Relative Strength Index (RSI) 30.05 29.79
Support Level $10.14 $1.31
Resistance Level $11.15 $2.22
Average True Range (ATR) 0.26 0.09
MACD -0.03 0.26
Stochastic Oscillator 0.00 58.88

Price Performance

Historical Comparison
EEA
TENX

About EEA The European Equity Fund Inc.

European Equity Fund, Inc / MD is a United States-based diversified, closed-end management investment company. The fund seeks long-term capital appreciation through investment in equity and equity securities of issuers domiciled in Europe. Its portfolio of investments consists of different sectors such as industrials, financials, healthcare, consumer discretionary, materials, consumer staples, information technology, and other sectors.

About TENX Tenax Therapeutics Inc.

Tenax Therapeutics Inc is a phase three, development-stage pharmaceutical company focused on identifying and developing therapeutics that address cardiovascular and pulmonary diseases with high unmet medical need, with an initial therapeutic focus on pulmonary hypertension. Its drug development pipeline comprises: Levosimendan, a novel, first-in-class K-ATP activator and calcium sensitizer developed for intravenous use in hospitalized patients with acutely decompensated heart failure; and Imatinib, as a potential therapy for pulmonary arterial hypertension. The company is currently conducting clinical trials only for levosimendan as its prioritized product candidate to evaluate its potential to help patients with pulmonary hypertension.

Share on Social Networks: